Mucosal Impedance in Eosinophilic Esophagitis and the Effect of Treatment

Location:

Rochester, Minn.

Trial status:

Open for Enrollment

Why is this study being done?

Do patients with eosinophilic esophagitis have baseline increased esophageal mucosal impedance? And will treatment that reverses esophageal eosinophilia in patients, correct abnormalities in mucosal impedance?

Who is eligible to participate?

Inclusion criteria: - Adults ages 18-90 undergoing clinically indicated upper endoscopy - Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field on esophageal biopsy despite at least 6 weeks of twice daily proton pump inhibitor therapy - Patients undergoing clinically indicated upper endoscopy for indications other than dysphagia or GERD with normal appearing esophageal mucosa. Exclusion criteria: - Medical conditions such as severe heart or lung disease that preclude safe performance of endoscopy - Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome - Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy

Last updated:

6/3/2014

NCT ID:

NCT01953575

IRB Number:

13-005778